Biotech stock Rapt plummeted to a record low Tuesday after the Food and Drug Administration put two of its clinical studies on hold.

The post Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests appeared first on Investor’s Business Daily.